Full Breakdown
Lawsuit Targets FDA’s Lenient Enforcement Guidance on Unauthorized Vaping Products
7/15/2026, 4:30:46 AM
Legal Challenge Over New FDA Guidance
On July 14, 2026, a coalition of public-health organizations, pediatricians and parents filed a lawsuit in the U.S. District Court for the District of Maryland against the U.S. Food and Drug Administration (FDA). The complaint contests FDA guidance issued in May 2026 that would “not prioritize enforcement against certain unauthorized e-cigarettes and nicotine-pouch products if the companies have marketing applications under review.” The plaintiffs argue the guidance permits manufacturers to sell vapes and nicotine products without the legally required pre-market authorization.
Guidance That Alters Enforcement Priorities
The May guidance changes the agency’s traditional enforcement approach. Under the new policy, the FDA would defer action on unauthorized e-cigarette and nicotine-pouch products while the manufacturers’ marketing applications are pending, rather than pursuing immediate compliance actions. The guidance does not create a new licensing pathway; it merely postpones enforcement for products already in the review process.
Plaintiffs’ Position and Rationale
The suing coalition contends that the policy “allows some manufacturers to sell vapes and nicotine without the legally required license,” thereby exposing consumers—particularly youth—to products that have not undergone the FDA’s safety and efficacy review. By challenging the guidance, the plaintiffs seek a court order requiring the FDA to resume full enforcement of the pre-market authorization requirement for all vaping and nicotine-pouch products.
Potential Impact on Regulation and Public Health
If the court grants the plaintiffs’ request, the FDA may be compelled to enforce licensing requirements uniformly, potentially limiting the market entry of new vaping products and reinforcing existing restrictions aimed at reducing youth vaping. Conversely, a ruling in favor of the agency could preserve the current defer-enforcement approach, allowing manufacturers to continue sales while their applications are evaluated. The case underscores the tension between regulatory flexibility for industry and public-health protections in the evolving nicotine-product landscape.
